Bronchial thermoplasty reduces asthma exacerbation and improves quality of life in asthma with type 2 inflammation
Journal of Thoracic Disease · 2025-03 · 17 (3) · 1159-1168
DOI: 10.21037/jtd-24-1842 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thoracic Disease, 2025-03. Verfasst von Thanyaporn Angsuwatcharakorn und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Bronchial thermoplasty (BT) is suggested for asthma patients with type 2 inflammation who are not eligible for or unresponsive to biologic drugs. In this study, we aimed to study the effectiveness of BT in asthma patients with type 2 inflammation.
Methods
This is a retrospective observational analytic study that enrolled moderately-severe asthma patients with type 2 inflammation; who did not respond to medium-dosed inhaled corticosteroids, long-acting beta2-agonists, and at least one other controller; to receive BT. All patients did not respond to or could not afford biologics. We collected the Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Test (ACT), pulmonary function test, number of emergency department visits, and hospitalizations at baseline, 3-, 6-, and 12-month post-treatment. Adverse events were also recorded.
Results
Seventeen patients completed the 12-month follow-up after BT. There were significant improvements from baseline in total AQLQ scores from 3.57 [interquartile range (IQR): 2] to 4.88 [IQR: 2.3] (P=0.004). All AQLQ domains were significantly improved. The ACT score also significantly improved from 13 [IQR: 5] to 20 [IQR: 7] (P=0.004). There were significant decreases in emergency department visits from 4 [IQR: 11] to 2 [IQR: 5] (P=0.01), hospitalizations from 1 [IQR: 2] to 0 [IQR: 1] (P=0.03), systemic steroid dose used from 5 [IQR: 5] to 1.25 [IQR: 5] mg per day (P=0.03), and days of reliever used in 2 weeks from 14 [IQR: 6] to 0 [IQR: 3] (P=0.001). All Omalizumab was discontinued within 12 months after BT. Common adverse events were wheezing and dyspnea and no serious complications were found.
Conclusions
BT is an alternative and effective treatment for asthma with type 2 inflammation without serious complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Department of Medicine, Somdej Phra Phutthaloetla Hospital, Samut Songkhram, Thailand.
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
- Division of Pulmonology and Critical Care Medicine, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Division of Pulmonology and Critical Care Medicine, Department of Medicine, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Thailand.
- Maximizing Thai Children's Developmental Potential Research Unit, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Zitieren
APA
Angsuwatcharakorn, T., Savigamin, C., Thanthitaweewat, V., Leelayuwatanakul, N., Kawkitinarong, K., Thawanaphong, S., Wongkarnjana, A., Jaimchariyatam, N., Jirakran, K., Sittipunt, C., & Sriprasart, T. (2025). Bronchial thermoplasty reduces asthma exacerbation and improves quality of life in asthma with type 2 inflammation. Journal of Thoracic Disease, 17(3), 1159-1168. https://doi.org/10.21037/jtd-24-1842
Vancouver
Angsuwatcharakorn T, Savigamin C, Thanthitaweewat V, Leelayuwatanakul N, Kawkitinarong K, Thawanaphong S, et al. Bronchial thermoplasty reduces asthma exacerbation and improves quality of life in asthma with type 2 inflammation. Journal of Thoracic Disease. 2025;17(3):1159-1168. doi:10.21037/jtd-24-1842
BibTeX
@article{Angsuwatcharakorn2025,
author = {Angsuwatcharakorn, Thanyaporn and Savigamin, Chatuthanai and Thanthitaweewat, Vorawut and Leelayuwatanakul, Nophol and Kawkitinarong, Kamon and Thawanaphong, Sarita and Wongkarnjana, Amornpun and Jaimchariyatam, Nattapong and Jirakran, Ketsupar and Sittipunt, Chanchai and Sriprasart, Thitiwat},
title = {Bronchial thermoplasty reduces asthma exacerbation and improves quality of life in asthma with type 2 inflammation},
journal = {Journal of Thoracic Disease},
year = {2025},
volume = {17},
number = {3},
pages = {1159--1168},
doi = {10.21037/jtd-24-1842}
}
EUVIMED